Viking Therapeutics (NASDAQ:VKTX) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday.
A number of other brokerages also recently issued reports on VKTX. Maxim Group reissued a “buy” rating and set a $5.00 price target on shares of Viking Therapeutics in a report on Monday, September 11th. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Viking Therapeutics in a report on Friday, November 10th. Finally, Roth Capital started coverage on shares of Viking Therapeutics in a report on Tuesday, November 21st. They set a “buy” rating and a $5.00 price target on the stock.
Shares of Viking Therapeutics (VKTX) traded down $0.02 during midday trading on Friday, reaching $3.02. 732,375 shares of the company were exchanged, compared to its average volume of 324,724. Viking Therapeutics has a 12-month low of $0.88 and a 12-month high of $3.24.
A number of institutional investors and hedge funds have recently bought and sold shares of VKTX. Renaissance Technologies LLC lifted its holdings in Viking Therapeutics by 62.9% during the first quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock valued at $388,000 after purchasing an additional 102,600 shares in the last quarter. Virtu KCG Holdings LLC purchased a new position in Viking Therapeutics during the second quarter valued at $124,000. Sabby Management LLC purchased a new position in Viking Therapeutics during the second quarter valued at $525,000. Sphera Funds Management LTD. purchased a new position in Viking Therapeutics during the third quarter valued at $554,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Viking Therapeutics in the third quarter valued at about $108,000. 7.50% of the stock is currently owned by institutional investors and hedge funds.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.